A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s

A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s

Submitted by admin on October 30, 2023 - 8:21pm
Source: 
BioPharma Dive
News Tags: 
Maplight Therapeutics
funding
schizophrenia
Headline: 
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
snippet: 

MapLight Therapeutics’ Series C round saw participation from new investors Novo Holdings, 5AM Ventures and Cowen Healthcare Investments.

Do Not Allow Advertisers to Use My Personal information